TARA · Protara Therapeutics, Inc.
$3.85
-0.05 (-1.28%)
At close · Aug 21
Market Cap
$229.29M
Shares
59.10M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.85
Open$3.91
Day$3.81–3.95
52W close$3.03–7.56
Avg vol 30d377K
Short int4.5M · 7.6% float · 11.5d
Short vol56%
Last earningsMay 13, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 11
Raw chart and full-history price indicators begin at the captured split on Jan 10, 2020; bars on opposite sides are not compared.
Up next
Next earnings call
May 13, 2028
Est · unconfirmed
· in 90 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−26%
below
Price vs 50-day avg
−4%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
18%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−4%
trailing
6-month return
−36%
trailing
YTD return
−28%
this year
Relative strength
−47%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+3% holders QoQ · +25 funds added
Insider flow
Distributing
Net -$882.2K over 90 days · 100% sells
Short interest
Falling
7.61% of float · ▼ -1.0% MoM · 11.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
118 holders — near 3-yr high, broad support
Squeeze score
57
elevated · 0–100
Fundamentals
EPS growth
+38%
Y/Y
Free cash flow
$-56.5M
Balance sheet
$49.7M
net cash
Quant / Vol
risk profile
Volatility
78%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
4.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−26%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
18%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+3% holders QoQ · +25 funds added
Insider flow
Distributing
Net -$882.2K over 90 days · 100% sells
Short interest
Falling
7.61% of float · ▼ -1.0% MoM · 11.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
118 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $4 · 18%
Range high $8
vs 200-day avg -26%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TARA
this stock
Protara Therapeutics, Inc.
|
$229.29M | -27.8% | — | — | 7.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +20.9% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.56B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Jan 10, 2020; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TARA | -3.0% | -4.2% | -35.5% | -1.8% | -27.8% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | -1.7% | -7.9% | -47.1% | -4.3% | -40.1% |
Key facts
CIK
1359931
CUSIP
74365U107
13F (30d)
111 filings
111 filers
Visit website
Investor relations